Danaher Corporation (DHR)
| Market Cap | 186.23B |
| Revenue (ttm) | 22.52B |
| Net Income (ttm) | 4.40B |
| Shares Out | 740.69M |
| EPS (ttm) | 5.89 |
| PE Ratio | 42.69 |
| Forward PE | 31.40 |
| Dividend | $1.08 (0.43%) |
| Ex-Dividend Date | Jun 28, 2024 |
| Volume | 1,505,781 |
| Open | 249.62 |
| Previous Close | 249.55 |
| Day's Range | 249.00 - 251.53 |
| 52-Week Range | 182.09 - 259.00 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 272.50 (+8.38%) |
| Earnings Date | Apr 23, 2024 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and service... [Read more]
Financial Performance
In 2023, Danaher's revenue was $23.89 billion, a decrease of -10.33% compared to the previous year's $26.64 billion. Earnings were $4.74 billion, a decrease of -33.23%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for DHR stock is "Buy." The 12-month stock price forecast is $272.5, which is an increase of 8.38% from the latest price.
News
Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensiti...
Danaher to Present at Bank of America Securities Healthcare Conference
WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securit...
Danaher Announces Quarterly Dividend
WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common sto...
Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry
WOBURN, Mass. , May 3, 2024 /PRNewswire/ -- Curiox Biosystems Co. Ltd (Curiox), a leader in the innovation of life science research technologies, and Beckman Coulter Life Sciences, a global leader in ...
The Forgotten Stock Advice That Delivers 170%+ Payout Growth
One of the best ways to grab a dividend payer set to surge is a strategy you never hear about anymore: Pick up shares of a conglomerate.
What Should You Do With Danaher Stock At $250 After Q1 Beat?
Danaher stock (NYSE: DHR), a conglomerate with products in life sciences, biotechnology, and diagnostics fields, recently posted its Q1 results that exceeded the street expectations. The company repor...
Danaher Shrugs Off Outlook for Falling Sales
The medical company reported first-quarter adjusted earnings of $1.92 a share, beating Wall Street's call for $1.72.
Danaher beats quarterly estimates on strength in diagnostics business
Danaher beat quarterly profit and sales expectations on Tuesday, driven by strength in its diagnostics and bioprocessing businesses, sending shares of the life sciences firm up more than 7% before the...
Danaher Reports First Quarter 2024 Results
WASHINGTON, April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29, 2024. All results in this release reflect only conti...
Danaher Schedules First Quarter 2024 Earnings Conference Call
WASHINGTON , March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 ...
Danaher to Present at TD Cowen Health Care Conference
WASHINGTON , Feb. 27, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conferen...
Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets
WASHINGTON , Feb. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with ...
Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development
Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expa...
Danaher forecasts revenue decline in 2024, shares fall
Life sciences firm Danaher forecast a low single-digit percentage decline year-over-year in its 2024 adjusted core revenue on Tuesday, sending the shares down nearly 4% before the bell.
Danaher Reports Fourth Quarter and Full Year 2023 Results
WASHINGTON , Jan. 30, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023. All results in this release reflect only ...
Charts turn bullish on health-care stocks as sector takes early lead in 2024
Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts h...
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devast...
Danaher CEO to Comment on Financial Performance
WASHINGTON , Jan. 8, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Compan...
Danaher to Present at J.P. Morgan Healthcare Conference
WASHINGTON , Jan. 2, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
Danaher Schedules Fourth Quarter 2023 Earnings Conference Call
WASHINGTON , Dec. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 202...
Will Danaher Stock Rebound To Pre-Inflation Shock Highs Of $300?
Danaher stock (NYSE: DHR), a conglomerate with products in environmental, life sciences, and diagnostics fields, trades at $220 per share, about 2% below the level seen in March 2021. DHR stock was tr...
Danaher completes $5.7 billion acquisition of Abcam
Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.
Danaher Completes Acquisition of Abcam
WASHINGTON , Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for...
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (Nasdaq: ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a def...